CAR

ImmPACT Bio to Present at Cell & Gene Meeting on the Mesa

Retrieved on: 
Tuesday, October 3, 2023
CAR, Cancer, Q&A, Mesa, Cell, Vaccine, Pharmaceutical industry

LOS ANGELES, Oct. 3, 2023 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT BIO"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2023 Cell & Gene Meeting on the Mesa, being held October 10-12, 2023 in Carlsbad, CA.

Key Points: 
  • LOS ANGELES, Oct. 3, 2023 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT BIO"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2023 Cell & Gene Meeting on the Mesa, being held October 10-12, 2023 in Carlsbad, CA.
  • Sumant Ramachandra, M.D., Ph.D., ImmPACT Bio's president and chief executive officer, will present a corporate update and participate in a Q&A session on Wednesday, October 11, 2023 at 3:15 PM PT.

Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201

Retrieved on: 
Monday, October 2, 2023
Rheumatology, Food, Survival, Woman, Infertility, Skin manifestations of sarcoidosis, Lupus, Scleroderma, Myositis, CAR, Investigational New Drug, Patient, Risk, Autoimmune disease, Diagnosis, Mortality, American College, FDA, Pulmonary hypertension, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Systemic scleroderma, Skin, Autoantibody, Pharmaceutical industry

PHILADELPHIA, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company’s third Investigational New Drug (IND) application for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, has been allowed to proceed by the U.S. Food and Drug Administration (FDA) for a Phase 1/2 study in patients with systemic sclerosis (SSc). The Company plans to initiate a Phase 1/2 clinical trial of CABA-201 across two parallel SSc cohorts – one cohort of six patients with severe skin manifestations and a separate cohort of six patients with severe organ involvement associated with systemic sclerosis. Consistent with the previously announced CABA-201 IND clearances for lupus and myositis, the starting dose for the trial, 1 x 106 cells/kg, was informed by the high degree of similarity between CABA-201 and the CD19-CAR T construct administered to a patient with severe, diffuse SSc in the recent Annals of Rheumatic Diseases publication.

Key Points: 
  • The Company plans to initiate a Phase 1/2 clinical trial of CABA-201 across two parallel SSc cohorts – one cohort of six patients with severe skin manifestations and a separate cohort of six patients with severe organ involvement associated with systemic sclerosis.
  • SSc affects approximately 88,000 patients in the U.S., and typically affects middle-aged individuals, particularly women.
  • Standard treatment options, which have modest effects, include generalized immunosuppressive agents or drugs targeted to specific symptomatic manifestations.
  • Due to the lack of adequate treatments, the risk of mortality in systemic sclerosis remains high, with an average survival of approximately 12 years following diagnosis.

Cimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine

Retrieved on: 
Friday, September 29, 2023
Research, Genetics, Health Technology, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Biozentrum University of Basel, Drug development, University, DBM, Bone marrow, Toxicity, Antibody, Stem cell, CD45, CAR, AML, Nephrology, Journal, Medical research, Patient, CD123, Blood, Therapy, CD117, Acute myeloid leukemia, Autoimmunity, Vaccine, Immunotherapy

The findings have broad implications for the development of novel therapies for hematologic conditions and the emerging field of epitope editing.

Key Points: 
  • The findings have broad implications for the development of novel therapies for hematologic conditions and the emerging field of epitope editing.
  • This seminal work is the basis of a new field of research called epitope editing, which has the potential to enable the development of therapies for patients with numerous hematologic diseases not previously possible.
  • The foundational patent for epitope editing is exclusively licensed to Cimeio.
  • Potent targeted therapies include antibodies, antibody-drug conjugates, T cell engagers, and even CAR T cells,” said Stefanie Urlinger, Ph.D., Chief Scientific Officer at Cimeio Therapeutics.

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Triple-negative breast cancer, Society, Euronext Growth, San Diego Convention Center, SITC, Immunotherapy, PDT, EDT, CAR, Journal, JITC, Poster, MUC1, Vaccine, Cellectis

Laurent Poirot, SVP Immunology of Cellectis, will present a poster on the benefits of combining potency attributes for TALEN®-edited smart CAR T-cells targeting MUC1 in preclinical models of triple-negative breast cancer.

Key Points: 
  • Laurent Poirot, SVP Immunology of Cellectis, will present a poster on the benefits of combining potency attributes for TALEN®-edited smart CAR T-cells targeting MUC1 in preclinical models of triple-negative breast cancer.
  • Title: TGF-Beta Blockade Combined with Activation-Induced IL12 Secretion Synergize to Optimize Potency of MUC1-CAR T-cells in Preclinical Targeting of Triple-Negative Breast Cancer.
  • Date/Time: Poster will be on display Saturday, November 4th, 2023 from 9:00 a.m. to 8:30 p.m. PDT, at San Diego Convention Center, Hall A.
  • Full text of the abstract will be made public on October 31, 2023 at 9:00 a.m. EDT on the SITC website and in a Journal for ImmunoTherapy of Cancer (JITC) supplement published on Oct. 31st, 2023 at 6 a.m. PDT/9 a.m. EDT.

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Society, Research and development, Cancer, SITC, Immunotherapy, Research, CAR, Development, Society for Immunotherapy of Cancer, Kite Pharma, SAN, Therapy, Vaccine, Flour

Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells

Key Points: 
  • Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells
    Demonstration of Dagger™ Technology to Engineer CAR T cells to Selectively Eliminate CD70 Positive, Allo-Reactive Host Immune Cells
    SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced three preclinical poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5, 2023, in San Diego, CA.
  • These presentations will focus on the Company’s next generation AlloCAR T platform technologies and the foundation for an early-stage solid tumor product candidate, ALLO-182.
  • “We are excited to share some of the groundbreaking work from our research team as we define next generation platform technologies that are designed to enhance engraftment and expansion of our AlloCAR TTM product candidates,” said Zachary Roberts, M.D., Ph.D., Executive Vice President, Research & Development and Chief Medical Officer.
  • “We believe this important and foundational work could expand the potential of off-the-shelf CAR T products by improving their persistence and anti-tumor activity across multiple targets while also creating a path to reducing the intensity of conditioning therapy.”
    Poster Session Display Date and Time: Friday, Nov. 3, 2023, 9:00 a.m. - 7:00 p.m. PT
    Poster Session Display Date and Time: Saturday, Nov. 4, 2023, 9:00 a.m. - 8:30 p.m. PT
    Poster Session Display Date and Time: Friday, Nov. 3, 2023, 9:00 a.m. - 7:00 p.m. PT

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Triple-negative breast cancer, Abstract, TNBC, Society, TIL, SITC, Immunotherapy, Lyell, NSCLC, Lung cancer, CAR, Patient, SAN, EPI, Pharmaceutical industry, Medical imaging, Vaccine

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that six abstracts highlighting its broad pipeline of clinical and preclinical product candidates as well as a shortened TIL manufacturing process have been accepted for presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place in San Diego, Nov. 1-5, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that six abstracts highlighting its broad pipeline of clinical and preclinical product candidates as well as a shortened TIL manufacturing process have been accepted for presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place in San Diego, Nov. 1-5, 2023.
  • “Our presentations at SITC highlight the progress we are making on several fronts to advance new product candidates and technologies designed to generate potent and durable cell therapies for patients with solid tumors,” stated Dr. Gary Lee, chief scientific officer at Lyell.
  • Two additional presentations highlight the design of Lyell’s ongoing Phase 1 clinical trials in progress: LYL797, a ROR1-targeted CAR T-cell therapy being evaluated in a Phase 1 trial in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer, and LYL845, a tumor infiltrating lymphocyte (TIL) therapy being evaluated in a Phase 1 trial in advanced solid tumors.
  • Details on the six poster presentations are below:
    Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies
    Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)
    Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors

Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Abstract, Society, ACET, Bio, SITC, Immunotherapy, EDT, CAR, Journal, JITC, Annual general meeting, Society for Immunotherapy of Cancer, Medical imaging, Cancer

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held in San Diego, CA from November 1-5, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held in San Diego, CA from November 1-5, 2023.
  • Details of the poster presentation are as follows:
    Abstract Title: Assay Development and Quantitative Detection of ADI-001, a CD20-Targeted γδ1 CAR T Therapy, using AlloCell, a Universal Assay for Monitoring of “Off-the-Shelf" Allogeneic Cell Therapies
    These abstracts will be available as a supplement in the Journal for ImmunoTherapy of Cancer (JITC) on Tuesday, October 31, 2023 at 9:00 a.m. EDT on www.sitcancer.org .

Claudin 18.2-Targeted Immunotherapy Research Report 2023: Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry Perspective - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 27, 2023
Health, Pharmaceutical, Incidence, Partnership, ADCC, Bi-specific T-cell engager, TCE, Hook effect, Overalls, Survival, Big Pharma, Business, Research, Appetite, History, Immunotherapy, Zolbetuximab, CDC, Vomiting, CAR, Science, Patient, Corporation, Antibody, Cancer, European, ADCP, Spacecraft, BDL, R, Stomach, GLOW, III, Bispecific monoclonal antibody, Safety, Sales, Vaccine, Pharmaceutical industry, Fine chemical, Risk management, Medical imaging, Dietary supplement

The "Claudin 18.2-Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry Perspective" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Claudin 18.2-Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry Perspective" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive report offers valuable insights into the world of claudin 18.2 (CLDN18.2)-targeted antibody and cell therapy candidates, as of August 2023.
  • You'll delve into the industry landscape surrounding innovative claudin18.2-targeted antibody and cell therapy candidates.
  • The report shines a light on 48 companies actively engaged in research and development within this field, highlighting 68 unique product candidates.

Kyverna Therapeutics and ElevateBio to Advance Kyverna's Ingenui-T Cell Therapy Manufacturing

Retrieved on: 
Tuesday, September 26, 2023
Partnership, Good manufacturing practice, Mountaineering, Ingenui, Research, CAR, CGMP, Patient, Engineering, Vaccine

EMERYVILLE, Calif. and WALTHAM, Mass., Sept. 26, 2023 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases and ElevateBio, LLC ("ElevateBio"), a technology-driven company focused on powering transformative cell and gene therapies, today announced a partnership to advance process development and manufacturing to produce industry-leading Ingenui-T-derived chimeric antigen receptor (CAR) T-cell therapies. Ingenui-T is an optimized autologous manufacturing platform developed by Kyverna to specifically address the needs of patients with autoimmune diseases, enabling a lower cost of goods and an improved patient experience.

Key Points: 
  • ElevateBio and Kyverna will implement Kyverna's Ingenui-T platform into their process development and cell product manufacturing efforts at ElevateBio BaseCamp®.
  • BaseCamp is ElevateBio's end-to-end genetic medicine current Good Manufacturing Practice (cGMP) manufacturing and process development business with capabilities for research, clinical, and commercial cell and gene therapies.
  • "At ElevateBio, we have combined multiple next-generation technology platforms with industry-leading expertise to transform the current cell and gene therapy development paradigm," said Michael Paglia, chief operating officer at ElevateBio BaseCamp.
  • "We are delighted to build a long-term relationship with Kyverna to optimize manufacturing processes and accelerate the development of their therapies."

Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and CAR technology

Retrieved on: 
Monday, September 25, 2023
Lymphoma, Antigen, CSO, Colon cancer staging, Neoplasm, Max, Breast, NK, Prostate, Antibody, Lung, Molecular medicine, CAR, Incidence, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Hematological Cancer Research Investment and Education Act, Patient, Helmholtz Association, Mortality, Lymphocyte, Leukemia, Glycosylation, Uta, Epidemiology of cancer, Vaccine, Autoimmunity, Cancer

Berlin, Germany, 25 September 2023 – Glycotope GmbH (Glycotope) and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (GlycoTargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.

Key Points: 
  • Berlin, Germany, 25 September 2023 – Glycotope GmbH (Glycotope) and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (GlycoTargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.
  • However, in some indications, including harder to treat cancers with solid tumors, success has been limited.
  • In the scope of the newly established collaboration, highly tumor-specific antibodies developed by Glycotope will be combined with the CAR technology of the Max Delbrück Center to analyze their suitability for the treatment of solid tumors.
  • The CAR program at the Max Delbrück Center includes several proprietary antibody binders targeting hematologic tumors.